Quest Diagnostics (DGX) Panoramica del titolo
Quest Diagnostics Incorporated fornisce test e servizi diagnostici negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 5/6 |
DGX Community Fair Values
Create NarrativeSee what 32 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Quest Diagnostics Incorporated
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$246.45 |
| Massimo di 52 settimane | US$248.70 |
| Minimo di 52 settimane | US$171.18 |
| Beta | 0.55 |
| Variazione di 1 mese | 0.84% |
| Variazione a 3 mesi | 27.31% |
| Variazione di 1 anno | 34.23% |
| Variazione a 3 anni | 99.59% |
| Variazione a 5 anni | 60.98% |
| Variazione dall'IPO | 6,941.43% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Aug 08
DGX: Advanced Testing Expansion And Guidance Raise Will Support Balanced Outlook
Analysts have raised their blended price target for Quest Diagnostics from about $239 to roughly $246, citing recent Q2 beats, refreshed models, and expanding testing offerings in areas such as Alzheimer's disease, autoimmune conditions, and early cancer detection. Analyst Commentary Street research on Quest Diagnostics points to a generally constructive tone after Q2, with most firms lifting their price targets and refining models to reflect recent results and updated guidance.Articolo di analisi • Jul 26
Earnings Beat: Quest Diagnostics Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Quest Diagnostics Incorporated ( NYSE:DGX ) defied analyst predictions to release its second-quarter results, which...Aggiornamento narrativa • Jul 25
DGX: Advanced Diagnostics And AI Progress Will Support Balanced Risk Reward Profile
The analyst price target for Quest Diagnostics has been raised from $223.44 to $239.38, reflecting updated views that recent Q2 beats, higher guidance, and ongoing organic growth can support slightly stronger profit margins while keeping a similar P/E framework in place. Analyst Commentary Recent research on Quest Diagnostics points to a generally constructive stance, with most price targets moving higher after the Q2 report.Seeking Alpha • Jul 24
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results
Summary Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring. Valuation shows some opportunity, but total return forecast falls short of hurdle rate; sector-specific regulatory risks remain a challenge. Read the full article on Seeking AlphaArticolo di analisi • Jun 21
Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative
Recent Share Performance and Business Scale Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat. Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures. See our latest analysis for Quest Diagnostics. At a share price of...Aggiornamento narrativa • Jun 18
DGX: Advanced Diagnostics And AI Execution Will Support Safe Haven Appeal
Analysts have nudged their blended price targets on Quest Diagnostics higher, with a series of $5 to $20 upward revisions from multiple firms helping to justify only marginal tweaks to the model inputs and leaving the fair value estimate essentially unchanged at about $223.44 per share. Analyst Commentary Recent research on Quest Diagnostics clusters around a constructive stance, with several firms lifting price targets in increments of US$5 to US$20 while leaving underlying estimates and the blended fair value near US$223.44 per share.Aggiornamento narrativa • Jun 04
DGX: Raised 2026 Guidance And Execution Strength Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target nudged up by about $0.19 to roughly $223.44 as analysts fine-tuned assumptions around the discount rate, revenue growth, profit margins, and future P/E, following a series of recent target increases across major research firms. Analyst Commentary Recent research has converged around higher price targets for Quest Diagnostics, with several firms adjusting their models and one firm previously cutting its target while keeping a more tactical positive stance.Aggiornamento narrativa • May 13
DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal
Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.Aggiornamento narrativa • Apr 20
DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal
Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.Aggiornamento narrativa • Apr 05
DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile
Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.Aggiornamento narrativa • Mar 22
DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance
Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.Aggiornamento narrativa • Mar 07
DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings
Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.Aggiornamento narrativa • Feb 21
DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings
Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.Aggiornamento narrativa • Feb 06
DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings
Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.Aggiornamento narrativa • Jan 23
DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook
Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).Aggiornamento narrativa • Jan 06
DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook
Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.Aggiornamento narrativa • Dec 14
DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook
Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.Aggiornamento narrativa • Nov 29
DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook
The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.Aggiornamento narrativa • Nov 15
DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks
Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.Aggiornamento narrativa • Nov 01
DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum
Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.Aggiornamento narrativa • Oct 18
Preventive Diagnostics And Automation Will Shape Future Healthcare
Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.Rendimenti per gli azionisti
| DGX | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | 4.9% | -1.7% | -0.2% |
| 1Y | 34.2% | 16.9% | 12.1% |
Ritorno vs Industria: DGX ha superato il US Healthcare che ha restituito 16.9 % nell'ultimo anno.
Rendimento vs Mercato: DGX ha superato il mercato US che ha restituito 12.1 % nell'ultimo anno.
Volatilità dei prezzi
| DGX volatility | |
|---|---|
| DGX Average Weekly Movement | 3.7% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: DGX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di DGX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1967 | 51,500 | Jim Davis | www.questdiagnostics.com |
Quest Diagnostics Incorporated fornisce test e servizi diagnostici negli Stati Uniti. L'azienda sviluppa e fornisce servizi di informazione diagnostica, come test clinici di routine, non di routine e avanzati, test di anatomopatologia e altri servizi di informazione diagnostica. Fornisce inoltre servizi con il marchio Quest Diagnostics e con i marchi AmeriPath, Dermpath Diagnostics, ExamOne e Quanum a medici, ospedali, pazienti e consumatori, piani sanitari, agenzie governative, datori di lavoro, rivenditori, aziende farmaceutiche e assicuratrici, laboratori clinici commerciali e organizzazioni di accountable care attraverso una rete di laboratori, centri di assistenza ai pazienti, flebotomi negli studi medici, call center e flebotomi mobili, infermieri e altri professionisti della salute e del benessere.
Quest Diagnostics Incorporated Riepilogo dei fondamenti
| DGX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$27.20b |
| Utili (TTM) | US$1.06b |
| Ricavi(TTM) | US$11.56b |
25.7x
Rapporto P/E2.4x
Rapporto P/SDGX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| DGX Conto economico (TTM) | |
|---|---|
| Ricavi | US$11.56b |
| Costo del fatturato | US$7.72b |
| Profitto lordo | US$3.84b |
| Altre spese | US$2.78b |
| Utili | US$1.06b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 9.59 |
| Margine lordo | 33.19% |
| Margine di profitto netto | 9.15% |
| Rapporto debito/patrimonio netto | 71.2% |
Come si è comportato DGX nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.4%
Rendimento attuale del dividendo35%
Rapporto di remunerazioneDGX paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di DGX| Quest Diagnostics date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Oct 06 2026 |
| Data di pagamento dei dividendi | Oct 21 2026 |
| Giorni fino al dividendo Ex | 15 days |
| Giorni prima della data di pagamento dei dividendi | 30 days |
DGX paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di DGXAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/20 02:12 |
| Prezzo dell'azione a fine giornata | 2026/09/18 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Quest Diagnostics Incorporated è coperta da 37 analisti. 15 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Eric Coldwell | Baird |
| Adam Feinstein | Barclays |